PharmaFluidics

Technologiepark 82

9052 Zwijnaarde

BE

PharmaFluidics

Foundation date

29/12/2020

Sector

#Supplier & Engineering

Subsector

The absence of molecular amplification in proteomics and metabolomics means that researchers rely heavily on sensitive detection of a biomarker during analytical separation. In recent years, LC performance has been the limiting factor in such experiments as the incremental improvement of conventional columns stalls. 

Based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems, PharmaFluidics introduces a new generation of chromatography columns. The company’s know-how is the design and manufacturing of miniaturized separation columns by silicon micromachining. The perfect order in the stationary phase leads to unique benefits in terms of performance, reproducibility and robustness.

PharmaFluidics was founded in 2010 as a spin-off from the University of Brussels (VUB).

Upcoming events

Latest news

  • HERAN Partners co-leads the GBP 6,5m financing round of Hypervision Surgical to support the further development and commercial roll-out of their Hyperspectral Imaging platform

    Tuesday June 6th 2023

  • ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01

    Monday June 5th 2023

  • Biotalys continues to demonstrate strength of first biocontrol in latest global field trials

    Friday June 2nd 2023